Sudden cardiac arrest kills 300,000 Americans each year. The standard treatment—manual chest compressions—hasn't meaningfully changed in 60 years and achieves less than 10% survival in most communities.

In this episode, CPR Therapeutics founder and CEO Norman Paradis joins Dan Mazzucco to talk about developing the first multimodal automated CPR system. They discuss why emergency medicine gets "hand-me-downs" from cardiology, how circumferential compression delivers five times more force without breaking ribs, navigating exception from informed consent trials, building strategic relationships with major device companies, and why EFIC trial requirements create both the highest barrier and the strongest competitive moat.

This conversation is for medtech innovators who recognize that sometimes the biggest unmet needs hide in plain sight because no one wants to fund the early-stage R&D, and who understand that regulatory barriers can become competitive advantages if you're willing to climb them first.

Norman Paradis, MD, is the Founder and CEO of CPR Therapeutics, an NIH and NSF-funded medical device startup developing the first effective integrated system for cardiopulmonary resuscitation. He is Emeritus Professor of Emergency Medicine at Dartmouth and former Chief of Emergency Medicine at Dartmouth-Hitchcock Medical Center. Dr. Paradis received his medical degree from Northwestern University Feinberg School of Medicine in 1984 and completed his residency in emergency medicine at USC/LA General Medical Center. He has over 40 years of experience and has been active in biomedical innovation throughout his career, previously holding positions at University of Colorado, Columbia University, NYU, and Medical College of Virginia. Dr. Paradis served on the American Heart Association's Advanced Cardiac Life Support (ACLS) Subcommittee for over 10 years, is a founding member of SAEM's Reperfusion Working Group, and serves on editorial boards of The American Journal of Emergency Medicine, Resuscitation, and JAMA's Critical Illness section. He has published more than 50 papers in cardiology, critical care, and emergency medicine, and is senior editor of Cardiac Arrest: The Science and Practice of Resuscitation Medicine. Prior to CPR Therapeutics, he contributed to the development of NT-ProBNP (a widely used heart failure biomarker) and worked with multiple resuscitation technology startups.

Note: Dan's opening statement that this was the "last" episode in the season was just wrong. This interview was so good that it had to jump the queue.

A physician treating patients all day sees exactly what devices and treatments are needed. An AI engineer two floors up could solve that problem in an afternoon. The question is: how do you get them in the same building?

In this episode, Dr. Afshin Safavi, founder of Colorado Health and Tech Centers, joins Dan Mazzucco to discuss building innovation ecosystems through strategic real estate development. Their wide-ranging discussion explores a three-tier support model (space, funding, and mentorship) for early-stage companies; why mixing biotech, quantum, AI, cybersecurity, and space companies under one roof creates unexpected collaborations; Dr. Safavi's venture studio model; and the value of lunch-and-learns, among other things.

This conversation is for medtech founders skeptical about "value-adds" in innovation hubs.

Dr. Afshin Safavi is a founder, councilman, consultant, board member, entrepreneur, and investor in biotechnology, pharmaceutical, animal health, technology, and real-estate sectors with multi-billion-dollar turnovers in biological products and is responsible for multiple drug products in the market today. He is the founder of Colorado Health and Tech Centers (CHTC). Prior to that, he founded BioAgilytix Labs, one of the most successful multi-billion-dollar Contract Research Organizations known internationally. He has extensive experience establishing and leading teams in start-ups, as well as Fortune 500 biotech and pharmaceutical companies. He has worked with clients and companies in more than 30 countries.

A family tragedy exposes the massive gap between how well we fund cardiovascular disease versus conditions that affect one in three women; an entrepreneur decides to build the missing solution.

In this episode, Avana Health CEO and Co-Founder Peter Pacult joins Dan Mazzucco to talk about transforming personal loss into clinical innovation — navigating the underfunding crisis in women's health, strategic pivoting from postpartum hemorrhage to acute heavy menstrual bleeding, creatively designing a Phase 1 trial to serve a dual purpose as a pathology study, and building partnerships by understanding what truly matters to each stakeholder in healthcare.

This conversation is for medtech entrepreneurs who recognize that the biggest opportunities often hide in the areas that have been most neglected and who are ready to build solutions with both humility and strategic precision.

Peter Pacult, MBA, is the CEO and Co-Founder of Avana Health, a clinical-stage women's health company focused on treating critical unmet needs in uterine health. With over 20 years of experience in finance and life sciences, he has led multi-million dollar drug development programs and built high-performance teams from the ground up. Peter serves on the steering committee for the Gates Foundation and NIH Innovation Equity Forum for women's health, and holds advisory roles with the Women's Health Catalyst and the Turing Institute's AI for Women's Health Working Group. He holds an MBA from the University of Michigan Ross School of Business with a focus on leadership and strategy, and a BA in History from Northwestern University. At Avana Health, Peter is developing a novel drug-device platform to treat abnormal uterine bleeding (affecting at least one in three women) and postpartum hemorrhage (the leading cause of maternal death globally), with the goal of making treatment accessible in low-resource settings and maternal care deserts.

What happens when a marine biologist-turned recruiter teaches herself to code and ends up building FDA-regulated medical devices — all through the power of being "really nosy" about how teams work?In this episode, TechSlice CEO Juliana Buonanno joins Dan Mazzucco to talk about navigating the intersection of software development and medical device regulation — from her unconventional path into medtech, to cash-plus-equity partnership models that align founder and vendor incentives, to the critical pitfalls that sink medical software startups (over-engineering early prototypes, skipping regulatory pathways, hiring generic dev shops).This conversation is for medtech founders who know that building regulated products requires more than just great code — it requires partners who understand clinical workflows, FDA expectations, and when to say no to shiny features.Juliana Buonanno is the CEO (Emeritus) of TechSlice, a Maryland-based software development agency helping physician-entrepreneurs and MedTech innovators bring new medical and security technologies to life. Over the past eight years, She has led and advised startups and technical teams through the challenges of building FDA-regulated products—from early concept to market-ready solutions.Before founding TechSlice, Juliana helped lead an organizational transformation that turned a mid-sized software firm from a $1M annual loss into profitability within a year. At TechSlice, she has overseen the creation of medical monitoring devices, AI-driven diagnostic tools, and other products that sit at the intersection of healthcare and technology. Her work centers on improving how complex, regulated technologies are built—making the process faster, more transparent, and more effective.

Ann's passion lies in forging genuine connections to cultivate collaboration and unlock collective potential, driven by a desire to make a positive impact.

What happens when a deeply personal experience exposes a blind spot in women’s health and a team of entrepreneurs decides to build the device that should have existed all along?

In this episode, CleoCare co-founder Frederico Stock joins Dan Mazzucco to talk about turning real-world unmet need into a clinically meaningful product — navigating validation, usability, population risk, and med-device development trade-offs along the way.

This conversation is for entrepreneurs who build because problems in medicine won’t leave them alone.

Dan Mazzucco summarizes Season 1 of Life Science Insights and provides some teasers for Season 2.

Is your science truly investable, or just interesting?

Learn how early development decisions determine whether academic science can realistically become a drug, and how industry evaluates translatability long before the clinic.

This episode helps you understand what it really takes to turn promising academic science into a viable drug program. Dr. Vijayakumar explains how early development decisions, often made long before investors or regulators are involved, can determine whether a program succeeds or quietly fails. You’ll learn how industry evaluates “translatability,” how formulation and development strategy shape everything downstream, and why great science alone is not enough. If you want to know whether your research can realistically become a drug, and what thinking must change when moving from lab to clinic, this conversation provides a clear, grounded roadmap.

Know when to spin out your technology.

This conversation helps academic innovators decide whether (and when) spinning out a company is the right move. Dr. Riley shares a practical framework for assessing commercialization readiness, beyond publications and grant success. You’ll learn how timing, team composition, and institutional context affect outcomes, and why spinning out too early can be as risky as waiting too long. If you’re wrestling with whether to license, form a startup, or keep developing your technology in the lab, this episode offers clarity, perspective, and decision-making confidence grounded in real translational experience.

Entrepreneurship without the mythology.

An honest look at what it takes to build a medtech company, from customer discovery to leadership realities beyond the technology.

This episode gives an honest look at what it actually means to build and lead a medtech company. Eric Sugalski draws on experience as a repeat founder to explain the realities behind product development, customer discovery, and operational execution. You’ll gain insight into how founders spend their time, how service and product business models differ, and why leadership discipline matters as much as innovation. If you’re considering entrepreneurship or are already in it, this conversation helps align expectations with reality and prepares you for the non-technical challenges that define early company success.